Innocan Pharma Receives Third FDA Fee Waiver for Innovative Animal Drug Technology Innocan Pharma Corporation has achieved a third consecutive fee waiver from the FDA, enabling advancements in its innovative LPT-CBD product for chronic pain in dogs.

Innocan Pharma Receives Third FDA Fee Waiver for Innovative Animal Drug Technology #USA #Innocan_Pharma #LPT-CBD #FDA_Fee_Waiver #Herzliya,_Calgary